07/21/2026
Why Biosimilar FTO Searches Are the Most Complex in Pharma
The pharmaceutical industry has witnessed a remarkable shift over the last decade. As patents on blockbuster biologic drugs expire, biosimilars have emerged as one of the fastest-growing segments in healthcare. They promise greater patient access, lower treatment costs, and increased competition. Yet, behind every successful biosimilar launch lies one of the most challenging exercises in intellectual property: the Freedom to Operate (FTO) search.
Unlike conventional small-molecule drugs, where patent landscapes are often more straightforward, biosimilars exist in a web of overlapping patents, manufacturing trade secrets, regulatory exclusivities, and scientific uncertainties. An incomplete FTO analysis can expose a company to costly litigation, delayed product launches, or even complete market exclusion.
This article explores why biosimilar FTO searches are considered the most complex form of patent analysis in the pharmaceutical industry and what organizations must do to navigate this challenge successfully.
Understanding Freedom to Operate (FTO)
A Freedom to Operate search evaluates whether a product can be manufactured, used, marketed, imported, or sold in a particular jurisdiction without infringing active third-party intellectual property rights.
An FTO search does not determine whether an invention is patentable. Instead, it answers a more practical business question:
Can we commercialize this product without infringing someone else's patents?
For biosimilars, that seemingly simple question becomes extraordinarily difficult.
Why Biosimilars Are Different
Traditional pharmaceuticals are usually small molecules with well-defined chemical structures. Their manufacturing pathways are relatively standardized, making patent analysis comparatively manageable.
Biologics are fundamentally different.
They are large, highly complex proteins produced inside living cells. Even minor changes in the manufacturing process can alter the final product's characteristics.
A biosimilar is therefore not an exact copy of the reference biologic. Instead, it must demonstrate that there are no clinically meaningful differences in terms of safety, purity, and efficacy.
This scientific complexity directly translates into intellectual property complexity.
The Patent Landscape Extends Far Beyond the Core Molecule
Many people assume that once the original composition-of-matter patent expires, competitors are free to enter the market.
In reality, that is rarely the case.
A single biologic product may be protected by dozens—or even hundreds—of patents covering different aspects of the product and its lifecycle.
These patents may include:
Protein sequences
Modified amino acid variants
Glycosylation profiles
Formulations
Dosage regimens
Manufacturing processes
Cell lines
Purification techniques
Storage conditions
Delivery devices
Combination therapies
Methods of treatment
Diagnostic applications
Even if the primary patent has expired, many secondary patents may remain enforceable for years.
An FTO search must therefore evaluate every relevant patent family—not just the original invention.
Manufacturing Creates the Biggest Challenge
For most biosimilars, the greatest infringement risk often lies not in the product itself but in how it is made.
Biologic manufacturing involves numerous sophisticated stages, including:
Cell line development
Vector construction
Cell culture optimization
Fermentation
Protein expression
Purification
Viral inactivation
Filtration
Stabilization
Fill-and-finish processes
Each of these stages can be protected by independent patents.
Changing even a single purification technique or culture condition may avoid one patent while potentially infringing another.
This creates a multidimensional FTO problem where manufacturing decisions and patent strategy become inseparable.
Patent Thickets Complicate Decision-Making
Biologics are often surrounded by what IP professionals call patent thickets.
A patent thicket is a dense network of overlapping patents owned by one or multiple organizations that collectively make market entry difficult.
Instead of identifying one blocking patent, analysts may need to evaluate hundreds of related patents with overlapping claims.
Some patents protect:
Specific manufacturing temperatures
Particular chromatography methods
Buffer compositions
Protein purification parameters
Formulation ingredients
Delivery mechanisms
Determining which claims are genuinely relevant requires both scientific expertise and advanced patent analysis.
Every Jurisdiction Has Different Patent Risks
Freedom to Operate is jurisdiction-specific.
A biosimilar that is clear to launch in Europe may still face infringement risks in:
United States
Japan
South Korea
China
Canada
Australia
Patent expiration dates, continuation applications, divisional patents, and litigation outcomes vary between jurisdictions.
Global biosimilar companies must therefore conduct country-by-country FTO analyses rather than relying on a single worldwide assessment.
Patent Families Continue to Evolve
Unlike many technology sectors, pharmaceutical patent portfolios remain highly dynamic.
Originator companies continuously strengthen their IP positions by filing:
Continuation applications
Divisionals
Continuations-in-part (where applicable)
New formulation patents
Manufacturing improvements
Process optimization patents
Device-related patents
An FTO search completed today may require significant updates six months later.
Continuous monitoring is therefore essential throughout product development.
Scientific Expertise Is Just as Important as Patent Expertise
Reading a patent is only part of the challenge.
The analyst must also understand:
Molecular biology
Immunology
Protein chemistry
Fermentation technology
Analytical characterization
Manufacturing workflows
Regulatory science
Without technical expertise, critical claim limitations may be misunderstood or overlooked.
This is why biosimilar FTO projects often involve multidisciplinary teams comprising patent professionals, scientists, regulatory specialists, and manufacturing experts.
Regulatory Pathways Add Another Layer of Complexity
Regulatory approval and patent clearance are separate issues—but they frequently intersect.
For example:
Patent dance procedures in certain jurisdictions
Regulatory exclusivities
Pediatric exclusivities
Data exclusivity periods
Interchangeability requirements
Label carve-outs
A product may receive regulatory approval yet still face patent litigation before commercialization.
An effective FTO strategy therefore aligns patent analysis with regulatory planning from the earliest stages of development.
Manufacturing Trade Secrets Increase Uncertainty
One of the most overlooked challenges is that many critical manufacturing details are never patented.
Instead, companies protect them as trade secrets.
Competitors may know the characteristics of the final biologic but not the precise manufacturing process used to achieve them.
Consequently, FTO analysts must assess published patents while also anticipating alternative manufacturing routes that reduce infringement risk.
This requires both legal analysis and process innovation.
Litigation History Cannot Be Ignored
Many biologics have already been involved in extensive patent litigation.
Court decisions often redefine:
Claim interpretation
Patent validity
Infringement standards
Enablement
Written description
Doctrine of equivalents
Ignoring previous litigation may lead to inaccurate risk assessments.
An effective biosimilar FTO review therefore incorporates both active patents and relevant judicial decisions.
Artificial Intelligence Is Transforming Biosimilar FTO
As biologic patent portfolios become increasingly complex, AI-powered tools are helping IP professionals work more efficiently.
Modern platforms can assist with:
Patent landscape mapping
Semantic prior art searches
Patent family clustering
Citation network analysis
Claim similarity detection
Technology trend visualization
However, AI should be viewed as an accelerator—not a replacement for expert judgment.
Complex claim interpretation, scientific context, and legal risk assessment still require experienced patent professionals.
Best Practices for Conducting a Biosimilar FTO
Organizations can reduce risk by adopting a structured approach:
Begin FTO analysis early in product development.
Review both product and process patents comprehensively.
Analyze patent families across all target markets.
Monitor continuation and divisional filings throughout development.
Evaluate litigation history and licensing activity.
Collaborate with scientists, manufacturing experts, regulatory specialists, and patent counsel.
Update the FTO regularly as the patent landscape evolves.
An FTO should be treated as a living strategic document rather than a one-time legal exercise.
The Business Impact of a Strong FTO Strategy
A comprehensive biosimilar FTO provides benefits beyond legal compliance.
It helps organizations:
Reduce litigation risk
Identify design-around opportunities
Inform manufacturing decisions
Support licensing negotiations
Strengthen investment decisions
Improve product launch planning
Increase confidence in commercialization strategies
In today's competitive biologics market, a robust FTO can become a significant competitive advantage.
Final Thoughts
Biosimilar Freedom to Operate searches represent one of the most demanding forms of intellectual property analysis. The complexity arises from the convergence of cutting-edge science, layered patent portfolios, evolving regulations, sophisticated manufacturing processes, and global commercialization strategies.
Success is not achieved by identifying a single blocking patent. It comes from building a comprehensive understanding of an intricate intellectual property ecosystem where every manufacturing decision, formulation choice, and jurisdictional difference can influence commercial freedom.
As the biosimilar market continues to expand worldwide, organizations that invest in thorough, continuously updated FTO analyses will be better positioned to launch products with confidence, manage legal risks proactively, and compete effectively in an increasingly crowded marketplace.
In the biosimilar industry, innovation alone is not enough. The ability to navigate the patent landscape strategically is often what determines who reaches the market first and who stays there.
